By Doug Young & Rene Vanguestaine
China Development Bank has become the target of the latest anti-corruption crackdown by China’s main graft buster. Will this affect China’s policy of lending big money to developing countries, and if so, what’s driving such a shift?
And AbbVie has filed a suit in the U.S. against BeiGene, one of China’s most up-and-coming young drug makers. What’s likely to happen next in this tug of war between the two companies’ similar blood cancer drugs? Exactly how expensive and destructive are such lawsuits to the companies involved?
About China Inc
China Inc by Bamboo Works discusses the latest developments on Chinese companies listed in Hong Kong and the United States to drive informed decision-making for investors and others interested in this dynamic group of companies.
Subscribe to China Inc on your favorite app: